Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

78.15 -0.81 (-1.03%)
Streaming Delayed Price Updated: 9:40 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
MINNEAPOLIS, MN / ACCESSWIRE / April 26, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for... 
From Celcuity Inc.
Via AccessWire
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (... 
Via Benzinga
Stocks That Hit 52-Week Highs On Friday
During the morning session on Friday, 178 stocks hit new 52-week highs. Noteworthy Points: Microsoft (NASDAQ:MSFT) was the largest firm on a market cap basis to set... 
Via Benzinga
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (... 
Via Benzinga
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
- Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected,... 
From Celcuity Inc.
Via AccessWire
55 Biggest Movers From Yesterday
Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with... 
Via Benzinga
What's Happening With ATNF Stock And CELC Stock?
180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher following insider buying from Marc Feldmann, a director on the company's board, and Jonathan Rothbard, the... 
Via Benzinga
42 Stocks Moving In Monday's Mid-Day Session
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the company's 13D filing showed that Modell's Sporting Goods had reported a stake... 
Via Benzinga
51 Biggest Movers From Friday
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and... 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges Over 100 Points; Provention Bio Shares Plunge
Toward the end of trading Friday, the Dow traded up 0.42% to 33,645.90 while the NASDAQ rose 0.06% to 13,837.33. The S&P also rose, gaining 0.32% to 4,110.11. The U.S. has the... 
Via Benzinga
Topics Stocks
Mid-Day Market Update: WD-40 Drops After Weak Q2 Results; Celcuity Shares Jump
Midway through trading Friday, the Dow traded up 0.28% to 33,598.84 while the NASDAQ fell 0.16% to 13,806.77. The S&P also rose, gaining 0.13% to 4,102.64. The U.S. has the... 
Via Benzinga
Topics Stocks
38 Stocks Moving In Friday's Mid-Day Session
Gainers Celcuity Inc. (NASDAQ: CELC) shares jumped 64.5% to $23.54 after the company announced a worldwide licensing agreement with Pfizer to develop and commercialize... 
Via Benzinga
How A Pfizer Cancer Drug Pact Launched Celcuity Stock Into A Breakout
Biotech stock Celcuity broke out and launched to near a two-year high Friday after it struck a licensing deal with Pfizer for a breast cancer treatment. 
Via Investor's Business Daily
Mid-Morning Market Update: Markets Open Higher; US Producer Prices Rise 1% In March
Following the market opening Friday, the Dow traded up 0.29% to 33,487.00 while the NASDAQ rose 0.01% to 13,748.50. The S&P also rose, gaining 0.21% to 4,097.50. The U.S. has... 
Via Benzinga
Topics Stocks
What's Going On With CELC Stock And PRVB Stock Today?
Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize... 
Via Benzinga
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc... 
Via Benzinga
30 Stocks Moving in Friday's Pre-Market Session
Gainers Celcuity Inc. (NASDAQ: CELC) rose 32.3% to $19.00 in pre-market trading after the company reported a worldwide licensing agreement with Pfizer to develop and... 
Via Benzinga
Celcuity Stock Moves Higher After Licensing Pact With Pfizer For Gedatolisib In Breast Cancer
Celcuity Inc (NASDAQ: CELC) has entered into a global licensing agreement with Pfizer Inc (NYSE: PFE), granting Celcuity exclusive rights to... 
Via Benzinga
10 Stocks Moving In Thursday's After-Hours Session
Gainers FuboTV (NYSE: FUBO) shares are trading higher after the company announced it acquired exclusive streaming rights to the Qatar World Cup 2022 Qualifying matches of South... 
Via Benzinga
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
From Celcuity Inc.
Via Business Wire
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
From Celcuity Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.